NCT01292798View on ClinicalTrials.gov

Ranibizumab 0.5mg and 2.0mg to Treat Diabetic Macular Edema in Patients With Poor Response to Bevacizumab

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions
Diabetic Macular Edema
Interventions
DRUG

Ranibizumab

0.05ml of 0.5mg or 2.0mg ranibizumab injected intravitreally

Trial Locations (5)

69815

Retina Institute of Hawai'i, Honolulu

93030

California Retina Consultants, Oxnard

93103

California Retina Consultants, Santa Barbara

93309

California Retina Consultants, Bakersfield

93454

California Retina Consultants, Santa Maria

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

California Retina Consultants

OTHER